If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
A committee of two Joint Drugs Controllers has been constituted at CDSCO to monitor the process of inspection, reporting, and subsequent action to ensure compliance to the Drugs & Cosmetics Act, 1940
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
Centre and states need to work in tandem and in a collaborative spirit as was done during the previous surges for COVID-19 prevention and management
Subscribe To Our Newsletter & Stay Updated
